Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma

Hormone and Metabolic Research

Volumn 44, Issue 5, 2012, Pages 367-372

  Timmers, H J L M ^a   Taieb, D ^b   Pacak, K ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TIMONE HOSPITAL   (France)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

FDA PET; FDG PET; FDOPA PET; MIBG scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; ADRENALIN C 11; FLUORODEOXYGLUCOSE F 18; HYDROXYEPHEDRINE C 11; PENTETREOTIDE IN 111; TRACER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; GENETIC ANALYSIS; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PHEOCHROMOCYTOMA AND PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

ADRENAL GLAND NEOPLASMS; ANIMALS; DIAGNOSTIC IMAGING; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84860833990     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1299712     Document Type: Review

References (46)

1. Lenders J W, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet: 2005; 366 665 675 (Pubitemid 41176020)
2. Timmers H J, Gimenez-Roqueplo A P, Mannelli M, Pacak K. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer: 2009; 16 391 400
3. Timmers H J, Kozupa A, Eisenhofer G, Raygada M, Adams K T, Solis D, Lenders J W, Pacak K. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab: 2007; 92 779 786 (Pubitemid 46465640)
4. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, Pignataro V, Bernini G, Giache V, Bacca A, Biondi B, Corona G, Di Trapani G, Grossrubatscher E, Reimondo G, Arnaldi G, Giacchetti G, Veglio F, Loli P, Colao A, Ambrosio M R, Terzolo M, Letizia C, Ercolino T, Opocher G. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab: 2009; 94 1541 1547
5. Bayley J P, Kunst H P, Cascon A, Sampietro M L, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers H J, Hoefsloot L H, Hermsen M A, Suarez C, Hussain A K, Vriends A H, Hes F J, Jansen J C, Tops C M, Corssmit E P, de Knijff P, Lenders J W, Cremers C W, Devilee P, Dinjens W N, de Krijger R R, Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol: 2010; 11 366 372
6. Qin Y, Yao L, King E E, Buddavarapu K, Lenci R E, Chocron E S, Lechleiter J D, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo R A, Toledo S P, Stiles C, Aguiar R C, Dahia P L. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genet: 2010; 42 229 233
7. Comino-Mendez I, Gracia-Aznarez F J, Schiavi F, Landa I, Leandro-Garcia L J, Leton R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gomez-Grana A, de Cubas A A, Inglada-Perez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernandez-Lavado R, Diaz J A, Gomez-Morales M, Gonzalez-Neira A, Roncador G, Rodriguez-Antona C, Benitez J, Mannelli M, Opocher G, Robledo M, Cascon A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genet: 2011; 43 663 667
8. Benn D E, Gimenez-Roqueplo A P, Reilly J R, Bertherat J, Burgess J, Byth K, Croxson M, Dahia P L, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka J L, Rohmer V, Tucker K, Jeunemaitre X, Marsh D J, Plouin P F, Robinson B G. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab: 2006; 91 827 836 (Pubitemid 43357746)
9. Lenders J W, Pacak K, Walther M M, Linehan W M, Mannelli M, Friberg P, Keiser H R, Goldstein D S, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA: 2002; 287 1427 1434 (Pubitemid 34250506)
10. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab: 2005; 16 66 72 (Pubitemid 40270852)
11. Shulkin B L, Wieland D M, Schwaiger M, Thompson N W, Francis I R, Haka M S, Rosenspire K C, Shapiro B, Sisson J C, Kuhl D E. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med: 1992; 33 1125 1131
12. Mann G N, Link J M, Pham P, Pickett C A, Byrd D R, Kinahan P E, Krohn K A, Mankoff D A. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol: 2006; 13 187 197 (Pubitemid 43157413)
13. Lynn M D, Shapiro B, Sisson J C, Beierwaltes W H, Meyers L J, Ackerman R M, Mangner T J. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology: 1985; 155 789 792 (Pubitemid 15042791)
14. Timmers H J, Chen C C, Carrasquillo J A, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams K T, Pacak K. Comparison of 18F-fluoro-L-DOPA. 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab: 2009; 94 4757 4767
15. Van Der Horst-Schrivers A N, Jager P L, Boezen H M, Schouten J P, Kema I P, Links T P. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas - experience and meta-analysis. Anticancer Res: 2006; 26 1599 1604
16. Taieb D, Sebag F, Hubbard J G, Mundler O, Henry J F, Conte-Devolx B. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma? Clin Endocrinol (Oxf): 2004; 61 102 108
17. Timmers H J, Eisenhofer G, Carrasquillo J A, Chen C C, Whatley M, Ling A, Adams K T, Pacak K. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf): 2009; 71 11 17
18. Timmers H J, Kozupa A, Chen C C, Carrasquillo J A, Ling A, Eisenhofer G, Adams K T, Solis D, Lenders J W, Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol: 2007; 25 2262 2269 (Pubitemid 46954653)
19. Loh K C, Fitzgerald P A, Matthay K K, Yeo P P, Price D C. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest: 1997; 20 648 658 (Pubitemid 28056835)
20. Fiebrich H B, Brouwers A H, Kerstens M N, Pijl M E, Kema I P, de Jong J R, Jager P L, Elsinga P H, Dierckx R A, van der Wal J E, Sluiter W J, de Vries E G, Links T P. 6-[F-18]Fluoro- l -dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I- metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab: 2009; 94 3922 3930
21. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann H P. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology: 2002; 222 507 512 (Pubitemid 34106126)
22. Taieb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, De Micco C, Barlier A, Palazzo F F, Henry J F, Mundler O. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf): 2008; 69 580 586
23. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, Neumann H P. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging: 2003; 30 689 694 (Pubitemid 36612951)
24. Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, Barlier A, Carmona E, De Micco C, Garcia S, Mancini J, Palazzo F F, Lavieille J, Zanaret M, Henry J F, Mundler O, Taieb D. Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: The case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf): 2011; 74 21 29
25. King K S, Chen C C, Alexopoulos D K, Whatley M A, Reynolds J C, Patronas N, Ling A, Adams K T, Xekouki P, Lando H, Stratakis C A, Pacak K. Functional Imaging of SDHx-Related Head and Neck Paragangliomas: Comparison of 18F-Fluorodihydroxyphenylalanine, 18F-Fluorodopamine, 18F-Fluoro-2-Deoxy-D- Glucose PET, 123I-Metaiodobenzylguanidine Scintigraphy, and 111In-Pentetreotide Scintigraphy. J Clin Endocrinol Metab: 2011; 96 2779 2785
26. Timmers H J, Hadi M, Carrasquillo J A, Chen C C, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams K T, Pacak K. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med: 2007; 48 1599 1606 (Pubitemid 47572706)
27. Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev: 2001; 22 502 548 (Pubitemid 32762325)
28. Timmers H J, Carrasquillo J A, Whatley M, Eisenhofer G, Chen C C, Ling A, Linehan W M, Pinto P A, Adams K T, Pacak K. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. J Nucl Med: 2007; 48 1940 1944 (Pubitemid 350232301)
29. Ilias I, Chen C C, Carrasquillo J A, Whatley M, Ling A, Lazurova I, Adams K T, Perera S, Pacak K. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med: 2008; 49 1613 1619
30. Kaltsas G A, Mukherjee J J, Grossman A B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol: 2001; 12 02 S47 S50 (Pubitemid 33069687)
31. van der Harst E, de Herder W W, Bruining H A, Bonjer H J, de Krijger R R, Lamberts S W, van de Meiracker A H, Boomsma F, Stijnen T, Krenning E P, Bosman F T, Kwekkeboom D J. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab: 2001; 86 685 693 (Pubitemid 32207482)
32. Bustillo A, Telischi F, Weed D, Civantos F, Angeli S, Serafini A, Whiteman M. Octreotide scintigraphy in the head and neck. Laryngoscope: 2004; 114 434 440 (Pubitemid 38391905)
33. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard J P, Wassef M, Le Cloirec J, Herman P, Tran Ba Huy P. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med: 2003; 44 1767 1774 (Pubitemid 39663308)
34. Koopmans K P, Jager P L, Kema I P, Kerstens M N, Albers F, Dullaart R P. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med: 2008; 49 1232 1237
35. Muros M A, Llamas-Elvira J M, Rodriguez A, Ramirez A, Gomez M, Arraez M A, Valencia E, Vilchez R. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun: 1998; 19 735 742 (Pubitemid 28407504)
36. Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, Stennert E, Schicha H. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging: 2002; 29 1571 1580
37. Telischi F F, Bustillo A, Whiteman M L, Serafini A N, Reisberg M J, Gomez-Marin O, Civantos F J, Balkany T J. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg: 2000; 122 358 362 (Pubitemid 30155313)
38. Huynh T T, Pacak K, Brouwers F M, Abu-Asab M S, Worrell R A, Walther M M, Elkahloun A G, Goldstein D S, Cleary S, Eisenhofer G. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol: 2005; 153 551 563 (Pubitemid 41556283)
39. Kaji P, Carrasquillo J A, Linehan W M, Chen C C, Eisenhofer G, Pinto P A, Lai E W, Pacak K. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol: 2007; 156 483 487 (Pubitemid 46672650)
40. Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo F F, Morange I, Niccoli-Sire P, Fakhry N, De Micco C, Cammilleri S, Enjalbert A, Henry J F, Mundler O. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med: 2009; 50 711 717
41. Timmers H J, Kozupa K, Chen C C, Carrasquillo J A, Ling A, Eisenhofer G, Adams K T, Solis D, Lenders J W, Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol: 2007; 26 2262 2269 (Pubitemid 46954653)
42. Gimenez-Roqueplo A P, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin P F, Rotig A, Jeunemaitre X. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab: 2002; 87 4771 4774 (Pubitemid 35247074)
43. Warburg O. On the origin of cancer cells. Science: 1956; 123 309 314
44. Battle M R, Goggi J L, Allen L, Barnett J, Morrison M S. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent. J Nucl Med: 2011; 52 424 430
45. Blankenberg F G. In vivo detection of apoptosis. J Nucl Med: 2008; 49 02 81S 95S (Pubitemid 351948038)
46. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol: 2011; 101 369 375